166 related articles for article (PubMed ID: 33497370)
1. Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.
Yu F; Zhang R; Zhang G; Meng Z; Liu X; He Y; Tan J; Wang R
Med Sci Monit; 2021 Jan; 27():e928796. PubMed ID: 33497370
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.
Xing YZ; Zhang K; Jin G
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840740
[TBL] [Abstract][Full Text] [Related]
3. The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves' disease and toxic nodular goitre.
Rogowski F; Abdelrazek S; Szumowski P; Zonenberg A; Parfienczyk A; Sawicka A
Nucl Med Rev Cent East Eur; 2011; 14(1):9-15. PubMed ID: 21751166
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
[TBL] [Abstract][Full Text] [Related]
5. Prediction of thyroidal
Zhang R; Zhang G; Wang R; Tan J; He Y; Meng Z
Oncotarget; 2017 Oct; 8(46):80934-80940. PubMed ID: 29113356
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes of Radioiodine Therapy for Juvenile Graves Disease with Emphasis on Subsequently Detected Thyroid Nodules: A Single Institution Experience from Japan.
Mizokami T; Hamada K; Maruta T; Higashi K; Tajiri J
Endocr Pract; 2020 Jul; 26(7):729-737. PubMed ID: 33471641
[TBL] [Abstract][Full Text] [Related]
7.
Zhao L; Zhang W; Xin Y; Wen Q; Bail L; Guan F; Bin J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):349-353. PubMed ID: 30413358
[TBL] [Abstract][Full Text] [Related]
8. [Predictors of the efficacy of radioiodine therapy of Graves' disease in children and adolescents].
Rumyantsev PO; Saenko VA; Dzeytova DS; Trukhin AA; Sheremeta MS; Slashchuk KY; Degtyarev MV; Serzhenko SS; Yasuchenia VS; Zakharova SM; Sirota YI
Probl Endokrinol (Mosk); 2020 Oct; 66(4):68-76. PubMed ID: 33351361
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
[TBL] [Abstract][Full Text] [Related]
10. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
Hu RT; Liu DS; Li B
BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
[TBL] [Abstract][Full Text] [Related]
12. Effect of Lugol's solution on
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Clin Exp Med; 2023 Jul; 23(3):825-831. PubMed ID: 35840869
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves' disease.
Liu M; Jing D; Hu J; Yin S
Am J Med Sci; 2014 Oct; 348(4):288-93. PubMed ID: 24805788
[TBL] [Abstract][Full Text] [Related]
14. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
15. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
16. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.
Horn-Lodewyk J
Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354
[TBL] [Abstract][Full Text] [Related]
17. Influence of (99m)Tc-pertechnetate thyroid imaging on radioactive iodine uptake.
Guo N; Yang K; Lin YS; Wang T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Jun; 36(3):267-70. PubMed ID: 24997818
[TBL] [Abstract][Full Text] [Related]
18. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
19. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
[TBL] [Abstract][Full Text] [Related]
20. Strategies of radioiodine therapy for Graves' disease.
Lind P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
